Breast Cancer Index Registry

TRIAL TITLE: Breast Cancer Index (BCI) Registry
TRIAL STATUS: Active, not recruiting
TRIAL NUMBER: NCT04875351
TRIAL PHASE: Observational (Patient Registry)

PARTICIPANTS IN THE STUDY:
• Diagnosed with hormone receptor-positive breast cancer that is stage 1, 2 or 3.
• Participants may have 0-3 positive lymph nodes (lymph nodes with cancer cells in them).
• Participants must have completed 4-7 years of hormone therapy after their initial surgery.
• Participants must have their pre-treatment tumor sample available for testing.

TRIAL DETAILS:
• Approximately 3,000 participants were recruited across 30-50 sites in the United States.
• Participants enrolled in study after completing their initial hormone therapy and completing Breast Cancer Index testing as part of their clinical care.
• The study will follow the outcomes of the study participants to confirm that the test can effectively predict the risk of recurrence (return of cancer).
• The study will also determine how the results of the test impact treatment decisions.

ABOUT THE BREAST CANCER INDEX TEST AND TREATMENT OF EARLY-STAGE HORMONE RECEPTOR-POSITIVE BREAST CANCER:
• Studies have shown that an extended course of hormone therapy (over 5 years) can improve outcomes for some, but not all, people with early-stage hormone receptor-positive breast cancer.1-4
• The Breast Cancer Index test is a tumor profiling test that was evaluated for its ability to predict a patient’s risk of recurrence and to pinpoint patients that receive a benefit from extended hormone therapy.5-7
• In 2021, the use of the Breast Cancer Index test to determine which patients benefit from extended hormone therapy was included in the National Comprehensive Cancer Network Guidelines.8
• Initial results from this study found that doctors change their recommendation for extended hormone therapy 40% of the time after Breast Cancer Index testing.9
REFERENCES: